An observational study in Stroke and Hemorrhagic Stroke, sponsored by EMVision Medical Devices Ltd. Recruiting at 8 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by EMVision Medical Devices Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Hemorrhagic Stroke with a site in United States — 22 open to participants now, 28 under way, 1 of them phase 3. Hemorrhagic Stroke · United States.
Among the 76 studies in Hemorrhagic Stroke with a site in United States, this one is the 9th largest by planned enrollment of the 19 observational ones that give a count, is one of 7 that started in 2025, is one of 19 observational ones, reaches primary completion later than 6 of the 27 other live ones, and was the 66th registered.
234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.
Browse Hemorrhagic Stroke studies →22 of the 76 studies in Hemorrhagic Stroke with a site in United States are open now. Recruiting first, the newest first:
Magnetic Tides · Sites in United States
Ages 18–80
University of Minnesota · Sites in United States
Ages 18+
phenox Inc. · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+
Joyce Chen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Hemorrhagic Stroke studies recruiting now, 36 (58%) set no upper age limit and 7 (11%) stop at 75 or younger; 5 take children under 18; 7 take healthy volunteers.
This study: 22 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is below the median of 379 across 75 observational studies indexed under Hemorrhagic Stroke.
Median enrollment 30 across the 57 interventional studies, 300 across the 19 observational. Of the 45 that completed or were terminated, 17 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 76 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with EMVision Medical Devices Ltd as lead sponsor.
EMVision Medical Devices Ltd has 1 study filed under Hemorrhagic Stroke — fewer than ten, so there is no comparison to draw.
11 of the studies in Hemorrhagic Stroke with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
| NCT04534556Baylor Research InstituteWireless Nerve Stimulation Device To Enhance Recovery After Stroke | 2027-01-01 |
| NCT07053917Johns Hopkins UniversityPsychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | 2027-02 |
| NCT07631078Magnetic TideskTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot | 2027-02-28 |
Add all 11 to your calendar (.ics) → With an account.
Among the 76 studies in Hemorrhagic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research is to evaluate a new investigational device for the diagnosis of stroke, the EMVision emu™ Brain Scanner. Stroke is the result of a blood clot stopping the normal flow of blood in the brain (ischaemic stroke) or a breakage in a blood vessel causing bleeding in the brain (haemorrhagic stroke). Stroke is a medical emergency and must be quickly diagnosed and treated. Computed tomography (CT) or magnetic resonance imaging (MRI) scans are commonly used to diagnose stroke, but they are not always readily available.
EMVision has developed the emu™ Brain Scanner, a helmet-like device which scans the head using ultra-high frequency radio signals. It is portable and easy to use, making it more accessible than CT or MRI machines. Easier access to the EMVision emu™ Brain Scanner may reduce the time taken to diagnose stroke, leading to faster treatment and better health outcomes. It is the purpose of this study in the first instance to determine the accuracy of the EMVision emu™ Brain Scanner in the detection of haemorrhagic stroke.
This clinical investigation is a paired diagnosis, diagnostic performance study intended to quantify the accuracy of the emu™ Brain Scanner's diagnostic output in comparison to current gold-standard practices including multi-modal neuroimaging by CT and/or MRI.
Any adult with neurological deficit suspected to be stroke shall be considered as potentially eligible for the study. Potential participant's eligibility for the study is determined via screening evaluation which includes a review of available demographic and medical history information against the study's inclusion and exclusion criteria, as well as a head size assessment using provided gauges to confirm that their head would fit within the emu™ Brain Scanner. If the screening evaluation finds that the participant is eligible for the study then the investigator proceeds with the informed consent process. This activity occurs in parallel with the investigational site's standard practices for stroke patient management, ensuring no delay in these patients' care.
Regardless of study participation, participants will receive the complete standard of care diagnostic workflow in accordance with applicable national and international guidelines, as well as practices established at the investigational site. The standard of care diagnostic workflow is centered around acute baseline multi-modal CT imaging (and in some instances MRI). Directly following or before this imaging, and without delaying subsequent treatment, a scan is completed with the emu™ Brain Scanner to allow timely coordination between the investigational emu™ Brain Scan result and the reference standard CT/MRI imaging. If the attending physician perceives any potential risk of delaying treatment of the patient then that patient is strictly exclude from the study, entirely at the attending physician's discretion.
A central adjudicating ground truth diagnosis panel is formed of experts in the area of stroke diagnosis and reviews all diagnostic information gathered by the investigational site as per the site's standard of care diagnostic workflow. The ground truth diagnosis panel is blinded to the output from the emu™ Brain Scanner and defines the 'ground truth' or 'reference standard' diagnosis for each patient to ensure accuracy and consistency. Integral to the ground truth diagnosis panel's consideration is the assessment by the core imaging lab, who similarly review all imaging provided by the investigational sites to ensure consistent input to the ground truth expert panel.
The result of the emu™ Brain Scan is compared to the ground truth diagnosis by a biostatistician to determine the accuracy of the emu™ Brain Scanner's diagnostic output (in terms of sensitivity and specificity) with the first output evaluated being intracranial haemorrhage detection in suspected stroke patients. The biostatistician then performs all statistical analyses against the study objectives in accordance with the Statistical Analysis Plan.
234 studies on the registry are indexed under Hemorrhagic Stroke; 94 are open to participants now.
This study's planned enrollment of 300 is below the median of 379 across 75 observational studies indexed under Hemorrhagic Stroke.
Browse Hemorrhagic Stroke studies →This is the only study on the registry with EMVision Medical Devices Ltd as lead sponsor.
Compared within Hemorrhagic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →
300 subjects across two study arms
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Brain Scan
Group B includes all patients enrolled in the study ultimately diagnosed with a condition other than intracranial haemorrhage, including ischaemic stroke, transient ischaemic attack, or any of a variety of stroke mimicking conditions.
Diagnostic Test: Brain Scan
The EMVision emu™ Brain Scanner is a device system which scans the human brain using radiofrequency techniques. The emu™ headset is placed on the head of a patient, enabling ultra-high frequency radio wave (also commonly referred to as microwave) signal propagation into the patient's head. The radio-waves reflect from and transmit through the tissue boundaries and are detected by the receiver antennae within the headset. The transceivers operate at very low-level signals in accordance with national and international safety thresholds. The scattered signals carry information on the scanned tissues.
Demonstrate haemorrhage detection sensitivity >80% and specificity >80%
Time frame: <30 minutes from acute baseline CT/MRI
Demonstrate the time to complete an emu™ Brain Scan is <15 minutes
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate safety of the device
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate usability of the device
Time frame: <30 minutes from acute baseline CT/MRI
Evaluate device deficiencies
Time frame: <30 minutes from acute baseline CT/MRI
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 19 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.